HOWL

Werewolf is a pre-revenue clinical-stage biopharma that its own auditors and management flag with explicit going-concern doubt. The 10-K states cash of $57.1M funds operations only 'into the fourth quarter of 2026' — not even twelve months out — and the company burned $60.3M in operating cash in FY2025 against a cumulative $475M accumulated deficit. There is no product, no recurring revenue (the only historical revenue came from the now-completed Jazz collaboration, leaving only contingent milestones 'if at all'), and no dedicated liquidity source beyond an ATM offering that management concedes is constrained by Form S-3 General Instruction I.B.6. Equity has collapsed 66% YoY to $24.8M and total assets fell 45%, while current liabilities ballooned 138% — the balance sheet is visibly unwinding.

The February 2026 restructuring is the tell: a 64% reduction in force and engagement of Piper Sandler to run a 'full range of strategic alternatives' — a sale, merger, asset licensing, or dissolution. Management explicitly names the downside scenarios of liquidation and bankruptcy where 'investors will lose all or part of their investment.' This is not a company investing to grow; it is a company preserving cash while shopping itself, having gutted the R&D engine (R&D down 21%) that would create the very value a buyer might pay for. The lead assets WTX-124 and WTX-330 read out Phase 1 data in Q2 2026, but management admits any further development 'will require additional funding' it does not have and is instead seeking a partner for.